Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspergillopepsin-2 is a proteolytic enzyme isolated from the fungus Aspergillus niger var. macrosporus[2][3][8]. It was previously classified as an aspartic protease but is now recognized as a glutamic protease with a catalytic glutamic acid residue at its active site[2][8]. The enzyme consists of two non-covalently bound chains (light and heavy), and its C-terminal region can bind to the active site cleft of another molecule in a substrate-like manner[2]. Aspergillopepsin-2 preferentially cleaves peptide bonds in proteins such as insulin at specific sites (e.g., Asn-Gln, Gly-Ala, Tyr-Thr)[2]. It belongs to the peptidase family G1 and is used industrially for its potent protein-digesting activity; it also has applications in food processing and dietary supplements for aiding digestion[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspergillopepsin-2.